FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) reported second quarter 2026 results and advanced its fibroblast-based pipeline, highlighted by first patient dosing in the Phase 1/2 trial of wound-care candidate CYWC628 for diabetic foot ulcers. The company completed three cGMP batches of CYWC628 and plans interim trial results in 2H 2026, with primary safety and efficacy data expected by year-end 2026.

FibroBiologics strengthened its balance sheet with a $9.0 million private placement ($3.0 million upfront and up to approximately $6.0 million via warrant exercises) and a $3.0 million public offering. For Q2 2026, research and development expenses were about $1.7 million versus $2.0 million a year earlier, while general and administrative expenses were stable at $2.4 million. Net loss was approximately $4.1 million, and cash and cash equivalents totaled about $3.5 million at June 30, 2026.

The company reported preclinical burn-wound data using human dermal fibroblast spheroids, received a USPTO notice of allowance for a wound-healing patent, and filed a provisional patent on oral delivery systems for fibroblast-based therapeutics. Upcoming milestones include an anticipated IND clearance for psoriasis candidate CYPS317 and planned IND submission for multiple sclerosis candidate CYMS101 in Q4 2026, as well as an IND amendment for its degenerative disc disease program.

Positive

• Q2 2026 R&D expenses decreased to about $1.7 million from $2.0 million year over year
• Completed three cGMP batches of CYWC628 drug product to support the DFU trial
• First patients dosed in Phase 1/2 CYWC628 trial for diabetic foot ulcers
• Closed $3.0 million public offering, adding to liquidity
• Executed $9.0 million private placement with $3.0 million upfront and up to $6.0 million via warrants
• Received USPTO notice of allowance for wound-healing patent using 3D spheroid fibroblasts

Negative

• Reported Q2 2026 net loss of approximately $4.1 million
• Ended June 30, 2026 with $3.5 million in cash and cash equivalents

News Explained

The active resale registration now permits selling stockholders to resell up to 12,530,613 shares, but FibroBiologics receives no proceeds from those resales; it could receive up to $6.3 million only if the June warrants are exercised for cash.

Market Context

Historical event 1078761 recorded a -3.26% 24-hour reaction after a CYWC628 manufacturing update. Th...

Analysis

Historical event 1078761 recorded a -3.26% 24-hour reaction after a CYWC628 manufacturing update. That comparator adds context to this trial-progress report, while the $4.1 million loss and low short positioning remain relevant watchpoints.

Key Figures

Private placement: $9.0 million Upfront proceeds: $3.0 million Potential warrant proceeds: $6.0 million +5 more

8 metrics

Private placement $9.0 million Second-quarter corporate update

Upfront proceeds $3.0 million Private placement

Potential warrant proceeds $6.0 million Upon exercise in full

Public offering $3.0 million Second-quarter financing update

R&D expenses $1.7 million Three months ended June 30, 2026

G&A expenses $2.4 million Three months ended June 30, 2026

Net loss $4.1 million Three months ended June 30, 2026

Cash and equivalents $3.5 million At June 30, 2026

Historical Context

5 past events · Latest: Jul 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 09	Board appointment	Positive	+5.4%	Kathleen Rubins joined the board, adding scientific and genomics experience.
Jul 07	Clinical manufacturing	Positive	-3.3%	Third CYWC628 batch completed manufacturing and entered safety and quality testing.
Jun 30	Conference participation	Neutral	+19.2%	FibroBiologics announced participation in a cell therapy virtual conference.
Jun 29	Private placement	Negative	+19.2%	The company closed a private placement with upfront proceeds and warrant funding potential.
Jun 26	Private placement	Negative	+12.7%	FibroBiologics announced a private placement with warrants and planned closing terms.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

FBLG's recent news responses diverged from the announcement tone in four of five events; the sole aligned event was a board appointment.

Key Terms

private placement, cgmp, hdf spheroids, ind clearance

4 terms

private placement financial

"Strengthened financial position through completion of a $9.0 million private placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

cgmp regulatory

"in accordance with FDA's Good Manufacturing Practices (cGMP)"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

hdf spheroids medical

"topical treatment with human dermal fibroblast (HDF) spheroids"

Three-dimensional clusters of human dermal fibroblast cells grown in the lab that mimic how skin-supporting cells behave in real tissue. Like a miniature, living model of skin structure, HDF spheroids are used in research to test drugs, cosmetics, wound-healing approaches and safety without relying on flat cell layers. Investors care because results from spheroid models can better predict clinical or regulatory outcomes, inform R&D progress, and affect the perceived value of biomedical or skincare pipelines.

ind clearance regulatory

"Anticipates IND clearance for the treatment of psoriasis"

IND clearance is regulatory authorization that allows a company to begin testing an experimental drug in human clinical trials. Think of it as a safety-passport from regulators confirming enough preclinical evidence exists to move from lab work to people; for investors it marks a major development milestone that de-risks the program’s path to approval, unlocks value-driving data milestones, and often influences funding, partnerships, and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers
- On track for interim results reporting in 2H 2026

HOUSTON, July 31, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Recent Highlights:

Clinical Updates:

• Initiation of patient dosing in the Company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs).
  • Completed manufacturing of three batches of the CYWC628 drug product in accordance with FDA's Good Manufacturing Practices (cGMP). Two of these batches have been released and the third batch will be released after it successfully passes all required safety and quality testing.

Financing:

• Strengthened financial position through completion of a $9.0 million private placement with $3.0 million upfront and up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants. Additionally, closed a $3.0 million public offering.

Preclinical Progress:

• Reported preclinical results suggesting that topical treatment with human dermal fibroblast (HDF) spheroids may reprogram the burn wound environment by dampening harmful inflammation, reshaping immune cell behavior, and reducing markers of scar-forming activity, within just eight days of injury.

Patent Portfolio:

• Received a notice of an allowance for a patent with the U.S. Patent and Trademark Office (USPTO) covering methods of treating and accelerating the healing of wounds by topically administering a composition comprising 3D spheroid fibroblasts together or with one or more fibroblast-derived materials. 
• Filed a provisional patent application with the USPTO covering oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract.

Conference Presentations:

• Presented poster presentations on the novel thymus organoid platform at the Keystone Symposia on Aging and Immunity; and preclinical data from its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting.
• Presented its proprietary thymus organoid technology to reboot the immune system and extend human life at the Alliance for Longevity Initiatives H-Span Summit in Washington DC.

Upcoming Milestones 

Wound Healing:

• Phase 1/2 clinical trial evaluating fibroblast-based spheroids product candidate, CYWC628, in DFU patients:
  • Expects to report interim results in the second half of 2026.
  • Anticipates completion and disclosure of primary safety and efficacy results by the end of 2026. 

Psoriasis:

• Anticipates IND clearance for the treatment of psoriasis with CYPS317, the Company's fibroblast spheroid product candidate, in the fourth quarter of 2026.

Multiple Sclerosis:

• Plans to submit an IND application with the U.S. Food & Drug Administration (FDA) for the treatment of multiple sclerosis with FibroBiologics' fibroblast spheroid product candidate, CYMS101, in the fourth quarter of 2026.

Degenerative Disc Disease:

• Plans to amend the IND clearance with the FDA to replace single-cell fibroblasts with fibroblast-derived chondrocyte spheroids derived from the CYWC628 master cell bank.

Pete O'Heeron, CEO and Founder of FibroBiologics, said, "With the first patient dosed in our CYWC628 trial, FibroBiologics has entered an important stretch as a clinical-stage company. Every milestone ahead builds on this one, and every data point will speak to what fibroblasts can do for patients. We are positioned for the catalysts ahead and eager to share our initial findings this year."

Financial Highlights for the Quarter Ended June 30, 2026

• Research and development expenses were approximately $1.7 million for the three months ended June 30, 2026, compared to approximately $2.0 million for the same period in 2025. The decrease was primarily due to decreased CRO costs of $0.3 million as clinical validation changed to manufacturing, and certain costs were capitalized to research and development supplies.

• General and administrative expenses were approximately $2.4 million for both the three months ended June 30, 2026 and 2025. The primary areas of net change are decreased personnel expenses of $0.2 million; increased professional fees of $0.1 million for accounting, legal and marketing expenses; decreased facilities expenses of $0.1 million; and increased listing expenses of $0.1 million. 

• For the three months ended June 30, 2026, FibroBiologics reported a net loss of approximately $4.1 million. The net loss for the three months ended June 30, 2026, was primarily due to research and development expenses and general and administrative expenses discussed above. 
  
  
• Cash and cash equivalents totaled approximately $3.5 million at June 30, 2026. 
  
  

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

Cautionary Statement Regarding Forward-Looking Statements 

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the status, timing and plans for manufacturing FibroBiologics' product candidates, the potential clinical benefits of fibroblasts and fibroblast-derived materials, plans for, and the anticipated timing of the initiation and completion of, FibroBiologics' current and future preclinical studies, clinical trials, and research and development programs, the robustness, progress, and momentum of FibroBiologics' research and development program, the potential indications for FibroBiologics' programs, and plans for, and the timing of, regulatory filings. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) the ability of FibroBiologics to successfully prosecute its patent applications; (e) FibroBiologics' ability to manufacture its product candidates; (f) FibroBiologics' ability to conduct clinical trials; and (g) the Company's ability to maintain compliance with applicable Nasdaq rules. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. 

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-reports-second-quarter-2026-financial-results-progresses-clinical-trial-evaluating-lead-wound-care-candidate-302840401.html

SOURCE FibroBiologics, Inc.

FAQ

What were FibroBiologics (FBLG) key financial results for Q2 2026?

FibroBiologics reported a Q2 2026 net loss of about $4.1 million. According to the company, research and development expenses were approximately $1.7 million, general and administrative expenses were about $2.4 million, and cash and cash equivalents totaled roughly $3.5 million at June 30, 2026.

How is FibroBiologics financing its operations after the Q2 2026 results?

FibroBiologics strengthened liquidity with a $9.0 million private placement and a $3.0 million public offering. According to the company, $3.0 million was received upfront, with up to approximately $6.0 million in additional gross proceeds possible upon full warrant exercise under the private placement.

What is the status of FibroBiologics’ CYWC628 diabetic foot ulcer trial as of Q2 2026?

FibroBiologics has initiated patient dosing in its Phase 1/2 CYWC628 trial for diabetic foot ulcers. According to the company, three cGMP batches of CYWC628 were manufactured, two released, and interim clinical results are expected in the second half of 2026, with primary data by year-end.

What upcoming clinical milestones did FibroBiologics (FBLG) outline for 2026?

FibroBiologics expects CYWC628 interim data in 2H 2026 and primary results by end-2026. According to the company, it also anticipates IND clearance for psoriasis candidate CYPS317 and plans to submit an IND for multiple sclerosis candidate CYMS101 in the fourth quarter of 2026.

How did FibroBiologics’ R&D and G&A expenses change in Q2 2026?

FibroBiologics’ Q2 2026 R&D expenses were about $1.7 million, down from $2.0 million a year earlier. According to the company, general and administrative expenses were approximately $2.4 million for both periods, with mix changes in personnel, professional fees, facilities, and listing-related costs.

What patent and preclinical advances did FibroBiologics report with its Q2 2026 update?

FibroBiologics received a USPTO notice of allowance for a wound-healing patent using 3D spheroid fibroblasts. According to the company, it also filed a provisional oral-delivery patent and reported preclinical burn-wound data suggesting fibroblast spheroids may modulate inflammation, immune behavior, and scar-associated markers.

What does CYWC628 represent in FibroBiologics’ pipeline strategy for FBLG shareholders?

CYWC628 is FibroBiologics’ fibroblast-based spheroid candidate for diabetic foot ulcers, now in Phase 1/2 testing. According to the company, the first patient has been dosed, and upcoming interim and primary results in 2026 are positioned as key clinical catalysts for its wound-care franchise.